田纳西州

我们是谁

  • 1 月 9, 2024
    A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )
  • 1 月 9, 2024
    ERASur研究:测试在有限转移性结直肠癌的常规系统疗法基础上增加全烧蚀疗法的效果
  • 1 月 8, 2024
    评估自体钙粘蛋白 17 嵌合抗原受体 (CAR) T 细胞疗法 CHM-2101 的 1/2 期研究
  • 1 月 8, 2024
    RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
  • 1 月 5, 2024
    Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
  • 8 月 31, 2023
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
  • 2 月 7, 2023
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer Without Liver Metastases
  • 12 月 8, 2022
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
  • 12 月 1, 2022
    Phase 2 Study of DKN-01 in Colorectal Cancer
  • 11 月 15, 2022
    Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)